Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK DDI of Lemborexant with Loestrin, Famotidine, or Fluconazole
NCT03451110Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2018
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lemborexant in Insomnia (3 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Maximum Observed Concentration at Day 27, Predose Drug Concentration at Day 15 and 6 more. Started Feb 2018; status: completed.
02
Drugs
lemborexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT03451110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03451110.